CuraGen Sacks 80 as Focus Turns to Nascent Pipeline | GenomeWeb

NEW YORK, June 19 - CuraGen has laid off 20 percent of its staff, or around 80- people, as it directs its focus on its pipeline of protein, antibody, and small molecule therapeutics, the company said today.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.